

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Thisted et al.

Confirmation No: 1994

Serial No.: 10/630,203

Group Art Unit: 1652

Filed: July 29, 2003

Examiner: R. Prouty

For: Alpha-Amylase Mutants with Altered Properties

**AMENDMENT AND PETITION TO CORRECT  
INVENTORSHIP UNDER 37 C.F.R. §1.48(b)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Please amend the above-captioned application as follows:

**IN THE INVENTORSHIP**

Please delete Thomas Thisted, Soren Kjaerulff and Claus Crone Fuglsang as inventors.

**REMARKS**

This petition is filed under 37 C.F.R. §1.48(b) in support of Applicant's correction of the inventorship of the above-captioned application.

The correct inventors were named in the application when filed. However, as a result of prosecution of the application, only Carsten Andersen is the inventor of the subject matter now claimed. Applicants acknowledge that the invention of Thomas Thisted, Soren Kjaerulff and Claus Crone Fuglsang is no longer being claimed in the application. Applicants therefore request that this petition be granted.

All required fees were charged to Novozymes North America, Inc.'s Deposit Account No. 50-1701 at the time of electronic filing. The USPTO is authorized to charge this Deposit Account should any additional fees be due.

Respectfully submitted,

Date: September 24, 2009

/Elias Lambiris, Reg. # 33728/  
Elias J. Lambiris, Reg. No. 33,728  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097